FDA Grants Breakthrough Device Designation to Gradient Denervation’s Pulmonary Artery System
Gradient Denervation Technologies Receives FDA Advanced Device Status for Its Pulmonary Arterial Denervation System
Gradient Denervation Technologies has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its innovative pulmonary denervation system.
This designation supports the accelerated development and review of medical devices that show implicit for offering further effective treatment for serious or life-changing conditions, while still meeting the FDA’s strict safety and effectiveness norms.
The grade Denervation System offers a minimally invasive, catheter-based approach to treating pulmonary hypertension associated with heart failure. It utilizes therapeutic ultrasound to target and disrupt the nerves surrounding the pulmonary roadway, aiming to improve symptoms and reduce disease progression.
Specifically tailored to match the structure of the pulmonary artery, the system uses established interventional approaches. The goal of the treatment is to reduce sympathetic nerve activity in the pulmonary vasculature, which in turn lowers vascular resistance and pulmonary artery pressure.
The PreVail- PH2 Early Feasibility Study is now open for registration, targeting cases who have pulmonary hypertension linked to left-sided heart disease, distributed as WHO Group 2 Pulmonary Hypertension.
This condition affects a large portion of heart failure cases, with numerous passing increased pulmonary vascular resistance.
This elevation in resistance is associated with higher threats of hospitalisation and mortality. At present, there are no approved medicines or device curatives in the United States for treating this case group.
The Breakthrough Device Designation is considered a crucial step forward in the development of this technology, which aims to offer a new treatment option for a group of cases with limited available curatives.